Literature DB >> 22853738

Oscillatory entrainment of subthalamic nucleus neurons and behavioural consequences in rodents and primates.

E C J Syed1, A Benazzouz, M Taillade, J Baufreton, K Champeaux, M Falgairolle, B Bioulac, C E Gross, T Boraud.   

Abstract

We investigated the functional role of oscillatory activity in the local field potential (LFP) of the subthalamic nucleus (STN) in the pathophysiology of Parkinson's disease (PD). It has been postulated that beta (15-30 Hz) oscillatory activity in the basal ganglia induces PD motor symptoms. To assess this hypothesis, an LFP showing significant power in the beta frequency range (23 Hz) was used as a stimulus both in vitro and in vivo. We first demonstrated in rat brain slices that STN neuronal activity was driven by the LFP stimulation. We then applied beta stimulation to the STN of 16 rats and two monkeys while quantifying motor behaviour. Although stimulation-induced behavioural effects were observed, stimulation of the STN at 23 Hz induced no significant decrease in motor performance in either rodents or primates. This study is the first to show LFP-induced behaviour in both rats and primates, and highlights the complex relationship between beta power and parkinsonian symptoms.
© 2012 The Authors. European Journal of Neuroscience © 2012 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22853738     DOI: 10.1111/j.1460-9568.2012.08246.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

1.  Oscillatory Activity in Basal Ganglia and Motor Cortex in an Awake Behaving Rodent Model of Parkinson's Disease.

Authors:  Claire Delaville; Ana V Cruz; Alex J McCoy; Elena Brazhnik; Irene Avila; Nikolay Novikov; Judith R Walters
Journal:  Basal Ganglia       Date:  2014-04-01

2.  Subthalamic low-frequency oscillations predict vulnerability to cocaine addiction.

Authors:  Mickael Degoulet; Alix Tiran-Cappello; Etienne Combrisson; Christelle Baunez; Yann Pelloux
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

3.  Frequency matters: beta-band subthalamic nucleus deep-brain stimulation induces Parkinsonian-like blink abnormalities in normal rats.

Authors:  Jaime Kaminer; Pratibha Thakur; Craig Evinger
Journal:  Eur J Neurosci       Date:  2014-08-21       Impact factor: 3.386

4.  Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.

Authors:  Kristin B Dupre; Ana V Cruz; Alex J McCoy; Claire Delaville; Colin M Gerber; Katherine W Eyring; Judith R Walters
Journal:  Neurobiol Dis       Date:  2015-11-14       Impact factor: 5.996

Review 5.  Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state.

Authors:  Adriana Galvan; Annaelle Devergnas; Thomas Wichmann
Journal:  Front Neuroanat       Date:  2015-02-05       Impact factor: 3.856

6.  Phase-Dependent Suppression of Beta Oscillations in Parkinson's Disease Patients.

Authors:  Abbey B Holt; Eszter Kormann; Alessandro Gulberti; Monika Pötter-Nerger; Colin G McNamara; Hayriye Cagnan; Magdalena K Baaske; Simon Little; Johannes A Köppen; Carsten Buhmann; Manfred Westphal; Christian Gerloff; Andreas K Engel; Peter Brown; Wolfgang Hamel; Christian K E Moll; Andrew Sharott
Journal:  J Neurosci       Date:  2018-12-14       Impact factor: 6.167

Review 7.  Subthalamic Nucleus Deep Brain Stimulation: Basic Concepts and Novel Perspectives.

Authors:  Clement Hamani; Gerson Florence; Helmut Heinsen; Birgit R Plantinga; Yasin Temel; Kamil Uludag; Eduardo Alho; Manoel J Teixeira; Edson Amaro; Erich T Fonoff
Journal:  eNeuro       Date:  2017-09-22

8.  Beta Frequency Oscillations in the Subthalamic Nucleus Are Not Sufficient for the Development of Symptoms of Parkinsonian Bradykinesia/Akinesia in Rats.

Authors:  Christina Behrend Swan; Derek J Schulte; David T Brocker; Warren M Grill
Journal:  eNeuro       Date:  2019-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.